Автоматизированный метод оценки остроты зрения у младенцев и детей ясельного возраста с использованием системы слежения за движением глаз

Executive Industry Relevance

Automated, objective measurement of visual acuity in infants and toddlers addresses a critical gap in early-stage translational research and pediatric biomarker development. The AACP system enables quantitative, reproducible assessment of visual function in non-verbal populations, supporting early discovery and validation of neurodevelopmental endpoints. This capability enhances predictive confidence for pediatric drug and device portfolios targeting visual and neurological development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables objective quantification of visual function in pre-verbal pediatric populations.
• Supports functional endpoint validation for neurodevelopmental and ophthalmic targets.
• Facilitates mechanistic de-risking by isolating sensory processing variables.
• Provides reproducible data for early-stage portfolio triage.

Screening & Assay Development

• Delivers standardized, automated visual acuity assays suitable for high-throughput pediatric screening.
• Ensures reproducibility and quantitative output through automated eye-tracking and behavioral analysis.
• Prepares validated systems for downstream compound or device evaluation in pediatric models.
• Enables reliable comparison of intervention effects on visual endpoints.

Translational & Preclinical Research

• Aligns with translational biomarker strategies for pediatric visual and neurological development.
• Supports continuity from early discovery through preclinical validation in disease-relevant systems.
• Reduces risk in advancing candidates targeting early childhood visual function.
• Provides mechanistic insight into developmental trajectories relevant to therapeutic intervention.

Pipeline & Workflow Integration

The AACP method integrates into the discovery-to-preclinical continuum for pediatric visual and neurodevelopmental research, enabling early, objective endpoint measurement and supporting lead identification and validation.

• Discovery Biology: Objectively tests visual function hypotheses in non-verbal pediatric models.
• Screening: Provides reproducible, quantitative acuity outputs for assay standardization.
• Analytics: Generates measurable endpoints for statistical comparison across age groups and interventions.
• Translational Research: Bridges early discovery with preclinical validation of visual biomarkers.
• Enterprise Reuse: Establishes a scalable, automated platform for repeated use across pediatric studies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces ambiguity in pediatric target validation.
• Operational Value: Automates and standardizes visual acuity assessment for scalability and reproducibility.
• Strategic Value: Enables earlier, data-driven go/no-go decisions for pediatric programs.
• Portfolio Impact: Supports risk-adjusted prioritization of candidates targeting early childhood visual and neurological endpoints.

Implementation Considerations

• Requires expertise in pediatric behavioral testing and eye-tracking analytics.
• Needs high-resolution digital display, calibrated webcam, and compatible analysis software.
• Demands cross-team standardization for consistent data acquisition and interpretation.
• Adaptable to various pediatric age ranges and developmental stages with protocol adjustments.
• Dependent on subject cooperation and attention span, with practical limits in certain populations.

Biopharma FAQs